How much funding has Arvinas raised?

Arvinas has raised $464.9M in total funding, most recently a Private Equity round.

Who are Arvinas's investors?

Arvinas's investors include Canaan Partners, 5AM Ventures, EcoR1 Capital, RTW Investments, RA Capital Management, Nasdaq Ventures.

Where is Arvinas headquartered?

Arvinas is headquartered in New Haven, Connecticut, United States.

What industry is Arvinas in?

Arvinas operates in Biotech, Healthcare, Life Sciences.

Arvinas

IPO

Targeted Protein Degradation Therapeutics

Public · New Haven, United States · Founded 2013 · $464.9M raised

Biotech

Healthcare

Life Sciences

Headquarters: New Haven, Connecticut
Employees: 201–500
Founded: 2013
Business Model: B2B
Website: arvinas.com

Total Funding: $464.9M
Last Round: $350.0M Private EquityNov 2023
Rounds: 4
Type: Public

About

Arvinas is a clinical-stage biopharmaceutical company and pioneer of PROTAC protein degrader technology, harnessing the body's own ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its pipeline spans oncology and neurology, with lead programs targeting the androgen receptor (ARV-110) and estrogen receptor (ARV-471) in partnership with Pfizer. The company's platform addresses historically undruggable targets, offering potential advantages over traditional inhibitor approaches.

Summary

Arvinas is a Biotech company based in New Haven, United States, founded in 2013. It has raised $464.9M in total across 4 rounds, most recently a $350.0M Private Equity round in Nov 2023. Investors include Canaan Partners, 5AM Ventures and EcoR1 Capital.

LinkedIn X (Twitter)